NCT02779257View on ClinicalTrials.gov

Pasireotide Treatment for Neuroendocrine Tumor

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
DRUG

Pasireotide

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

DRUG

Diazoxide

Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Maryland, Baltimore

OTHER